NASDAQ:FATE Fate Therapeutics Q3 2024 Earnings Report $2.43 -0.15 (-5.81%) Closing price 04:00 PM EasternExtended Trading$2.44 +0.01 (+0.33%) As of 07:57 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more. ProfileEarnings HistoryForecast Fate Therapeutics EPS ResultsActual EPS-$0.40Consensus EPS -$0.42Beat/MissBeat by +$0.02One Year Ago EPSN/AFate Therapeutics Revenue ResultsActual Revenue$3.07 millionExpected Revenue$0.88 millionBeat/MissBeat by +$2.19 millionYoY Revenue GrowthN/AFate Therapeutics Announcement DetailsQuarterQ3 2024Date11/12/2024TimeAfter Market ClosesConference Call DateTuesday, November 12, 2024Conference Call Time3:00PM ETUpcoming EarningsFate Therapeutics' Q3 2026 earnings is estimated for Thursday, October 29, 2026, based on past reporting schedulesConference Call ResourcesPress Release (8-K)Quarterly Report (10-Q)Earnings HistoryCompany ProfilePowered by Earnings DocumentsPress Release(8-K)Quarterly report(10-Q) Fate Therapeutics Earnings HeadlinesCureVac (NASDAQ:CVAC) versus Fate Therapeutics (NASDAQ:FATE) Head-To-Head ComparisonSeptember 22 at 2:15 AM | americanbankingnews.comFate Therapeutics To Present Off-The-Shelf CAR T Portfolio At ACR Convergence 2026September 16, 2026 | rttnews.comHere’s the stock symbol I’ve promisedWhitney Tilson of Stansberry Research has long recommended Berkshire Hathaway as a core retirement holding - but now he believes he's found something better. This under-the-radar company sits at the intersection of America's two most important industries, including AI, pays massive dividends, and attracted a famous money manager who put 60% of his multi-billion-dollar fund into it. Tilson is revealing the name and ticker symbol completely free - no credit card or email required.September 23 at 1:00 AM | Stansberry Research (Ad)Fate Therapeutics Announces Four ACR Convergence 2026 Abstracts Highlighting Off-the-Shelf CAR T-Cell Programs in Autoimmune DiseaseSeptember 16, 2026 | quiverquant.comQFate Therapeutics Selected for Four Presentations Highlighting its Off-the-Shelf CAR T-Cell Portfolio in Autoimmune Disease at ACR Convergence 2026September 16, 2026 | globenewswire.comFate Therapeutics, Inc. (NASDAQ:FATE) Given Consensus Recommendation of "Hold" by AnalystsSeptember 14, 2026 | americanbankingnews.comSee More Fate Therapeutics Headlines Get Earnings Announcements in your inboxWant to stay updated on the latest earnings announcements and upcoming reports for companies like Fate Therapeutics? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Fate Therapeutics and other key companies, straight to your email. Email Address About Fate TherapeuticsFate Therapeutics (NASDAQ:FATE) is a clinical-stage biopharmaceutical company focused on developing cellular immunotherapies for cancer and autoimmune diseases. The company uses its induced pluripotent stem cell (iPSC) platform to produce potentially off-the-shelf immune-cell therapies designed to be manufactured at scale and administered to multiple patients. Its research and development programs include iPSC-derived natural killer (NK) cell and T-cell therapies. Notable candidates have included FT596, an iPSC-derived NK-cell therapy, and FT819, an iPSC-derived T-cell therapy targeting CD19. Fate has evaluated its investigational therapies in clinical studies for hematologic malignancies and has pursued additional applications in solid tumors and autoimmune disorders. The company does not have commercially approved products. Founded in 2007 and headquartered in San Diego, California, Fate Therapeutics conducts its research and clinical development activities primarily in the United States, with clinical studies potentially involving sites in other regions. Scott Wolchko serves as the company's president and chief executive officer.View Fate Therapeutics ProfileRead more More Earnings Resources from MarketBeat Earnings Tools Today's Earnings Tomorrow's Earnings Next Week's Earnings Upcoming Earnings Calls Earnings Newsletter Earnings Call Transcripts Earnings Beats & Misses Corporate Guidance Earnings Screener Latest Articles Energy Transfer Taps the AI Power BoomFull Throttle: Kratos and GE Fire Up a Next-Gen Defense EngineSandisk Joins the S&P 100—Is the Index Flow, or the AI Story, Driving the Stock?Thor Industries Is Boring—And That May Be Its Biggest AdvantageAutoZone Shifts Gears, On Track to Reverse Course and Price RecoveryMeta’s Muse Highlights Arm’s Growing Role in AI InfrastructureOld Dogs, New Tech: 3 Legacy Stocks Powering the AI Boom Upcoming Earnings Costco Wholesale (9/24/2026)Micron Technology (9/30/2026)NIKE (10/1/2026)Accenture (10/1/2026)PepsiCo (10/8/2026)Delta Air Lines (10/9/2026)America Movil (10/13/2026)BlackRock (10/13/2026)Citigroup (10/13/2026)The Goldman Sachs Group (10/13/2026) Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
